About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

GlaxoSmithKline's Cervarix Drug Approved by EU

by VR Sreeraman on September 24, 2007 at 8:18 PM
Font : A-A+

GlaxoSmithKline's Cervarix Drug Approved by EU

British pharmaceutical giant GlaxoSmithKline said Monday that the European Union has allowed it to market Cervarix -- a drug used to treat cervical cancer.

"The decision (by the European Commission) to approve Cervarix for the European Union represents a great step forward for European women," GSK chief executive JP Garnier said in a statement.

Advertisement

"Physicians across Europe will now have access to this important vaccine to help protect women against cervical cancer, the second most common cancer in women," he added.

The EU consists of 27 nations, including Britain, France and Germany.

Source: AFP
SRM /J
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Guide to Brushing Your Teeth the Right Way
Resting Heart Rate
Is COVID-19 Vaccination during Pregnancy Safe?
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Signature Drug Toxicity 

Recommended Reading
Cervical Cancer - Incidence
Cervical cancer is the second most common cancer among women and is the primary cause of ......
Vinegar for Cervical Cancer Surveillance
Visual Inspection With Acetic acid (VIA) is a cheap and effective method detect cervical cancer .....
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use